02/01/2024 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
The Ministry of Health’s Drug Advisory Committee has recommended:
- Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to:
- diabetic macular oedema; and
- neovascular (wet) age-related macular degeneration.
Funding status
RFaricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024.
NRMAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.